Company intelligence / Profile preview

Bexion Pharmaceuticals

Covington, Kentucky, United Statesbexionpharma.com ↗

Ownership: Private
Employees: ~31
Development stage: Phase 2

Overview

Bexion has completed Phase 1 clinical trials in both adults and children with advanced solid tumors using BXQ-350 as monotherapy, demonstrating a strong safety profile with evidence of single agent activity across multiple solid tumor types. The company has completed enrollment in the open-label portion of its Phase 1b/2 ASIST trial evaluating BXQ-350 in combination with standard of care for newly diagnosed metastatic colorectal cancer patients. Additionally, Bexion has completed a proof-of-concept study for treating chemotherapy-induced peripheral neuropathy.

Therapeutic areas: OncologyNeurology
Modalities: BiologicsSphingolipid metabolism modulators
Industry: Biotech

Drug pipeline

2 assets

BXQ-350

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Bexion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bexion Pharmaceuticals.

Explore the full profile